CL2018003096A1 - Receptor antigenico quimerico (car) con dominios de union a antigenos a la region constante del receptor de celulas t beta (divisional de la solicitud 2195-2016). - Google Patents

Receptor antigenico quimerico (car) con dominios de union a antigenos a la region constante del receptor de celulas t beta (divisional de la solicitud 2195-2016).

Info

Publication number
CL2018003096A1
CL2018003096A1 CL2018003096A CL2018003096A CL2018003096A1 CL 2018003096 A1 CL2018003096 A1 CL 2018003096A1 CL 2018003096 A CL2018003096 A CL 2018003096A CL 2018003096 A CL2018003096 A CL 2018003096A CL 2018003096 A1 CL2018003096 A1 CL 2018003096A1
Authority
CL
Chile
Prior art keywords
car
receptor
constant region
beta
divisional
Prior art date
Application number
CL2018003096A
Other languages
English (en)
Inventor
Martin Pulé
Paul Maciocia
Original Assignee
Ucl Business Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52649058&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2018003096(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB201403905A external-priority patent/GB201403905D0/en
Priority claimed from GB201416908A external-priority patent/GB201416908D0/en
Application filed by Ucl Business Plc filed Critical Ucl Business Plc
Publication of CL2018003096A1 publication Critical patent/CL2018003096A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/7051—T-cell receptor (TcR)-CD3 complex

Abstract

LA PRESENTE INVENCIÓN SE RELACIONA CON UN RECEPTOR ANTIGÉNICO QUIMÉRICO (CAR) QUE COMPRENDE UN DOMINIO DE UNIÓN A ANTÍGENOS EL CUAL SE UNE SELECTIVAMENTE A LA REGIÓN CONSTANTE DEL TCR BETA 1 (TRBC1) O TRBC2, CÉLULAS, CÉLULAS T QUE COMPRENDEN EL CAR, Y EL USO DE ESTAS CÉLULAS PARA EL TRATAMIENTO DE UN LINFOMA O IEUCEMIA DE CÉLULAS T EN UN SUJETO.
CL2018003096A 2014-03-05 2018-10-30 Receptor antigenico quimerico (car) con dominios de union a antigenos a la region constante del receptor de celulas t beta (divisional de la solicitud 2195-2016). CL2018003096A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201403905A GB201403905D0 (en) 2014-03-05 2014-03-05 Method
GB201416908A GB201416908D0 (en) 2014-09-25 2014-09-25 Method

Publications (1)

Publication Number Publication Date
CL2018003096A1 true CL2018003096A1 (es) 2019-01-11

Family

ID=52649058

Family Applications (4)

Application Number Title Priority Date Filing Date
CL2016002195A CL2016002195A1 (es) 2014-03-05 2016-09-01 Receptor antigénico quimérico car con dominios de unión a antígenos a la región constante del receptor de células t beta
CL2018003096A CL2018003096A1 (es) 2014-03-05 2018-10-30 Receptor antigenico quimerico (car) con dominios de union a antigenos a la region constante del receptor de celulas t beta (divisional de la solicitud 2195-2016).
CL2019001568A CL2019001568A1 (es) 2014-03-05 2019-06-07 Un acoplador biespecifico de células t que comprende un primer dominio que se une a la región constante de tcr beta 1 (trbc1) o trbc2, y un segundo dominio capaz de activar una célula t. (divisional solicitud 201803096)
CL2019001567A CL2019001567A1 (es) 2014-03-05 2019-06-07 Anticuerpo conjugado que se une a la región constante del receptor de células t beta 1 (trbc1) o trbc2. (divisional solicitud 201803096)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2016002195A CL2016002195A1 (es) 2014-03-05 2016-09-01 Receptor antigénico quimérico car con dominios de unión a antígenos a la región constante del receptor de células t beta

Family Applications After (2)

Application Number Title Priority Date Filing Date
CL2019001568A CL2019001568A1 (es) 2014-03-05 2019-06-07 Un acoplador biespecifico de células t que comprende un primer dominio que se une a la región constante de tcr beta 1 (trbc1) o trbc2, y un segundo dominio capaz de activar una célula t. (divisional solicitud 201803096)
CL2019001567A CL2019001567A1 (es) 2014-03-05 2019-06-07 Anticuerpo conjugado que se une a la región constante del receptor de células t beta 1 (trbc1) o trbc2. (divisional solicitud 201803096)

Country Status (23)

Country Link
US (2) US20170066827A1 (es)
EP (2) EP3125934B1 (es)
JP (4) JP6767872B2 (es)
KR (3) KR102235201B1 (es)
CN (3) CN106068276B (es)
AU (3) AU2015225944B2 (es)
BR (1) BR112016020304B1 (es)
CA (1) CA2940564C (es)
CL (4) CL2016002195A1 (es)
CU (1) CU24475B1 (es)
DK (1) DK3125934T3 (es)
ES (1) ES2758173T3 (es)
HU (1) HUE047641T2 (es)
IL (3) IL278878B (es)
MX (3) MX2016010856A (es)
MY (1) MY173567A (es)
PE (2) PE20170125A1 (es)
PH (2) PH12016501646A1 (es)
PL (1) PL3125934T3 (es)
PT (1) PT3125934T (es)
RU (3) RU2021101502A (es)
SG (3) SG10201906460PA (es)
WO (1) WO2015132598A1 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11385233B2 (en) 2015-03-05 2022-07-12 Autolus Limited Methods of depleting malignant T-cells
US11885806B2 (en) 2014-03-05 2024-01-30 Autolus Limited Method for depleting malignant T-cells
GB201403972D0 (en) 2014-03-06 2014-04-23 Ucl Business Plc Chimeric antigen receptor
EP3200807B1 (en) * 2014-10-03 2021-03-10 Oxford University Innovation Limited Analysis of t-cell monotypia
CA2937157A1 (en) * 2016-07-25 2018-01-25 Ucl Business Plc Protein-based t-cell receptor knockdown
AU2018219887A1 (en) 2017-02-08 2019-08-22 Dragonfly Therapeutics, Inc. Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
CA3235295A1 (en) 2017-02-20 2018-08-23 Dragonfly Therapeutics, Inc. Proteins binding her2, nkg2d and cd16
EP3606956A1 (en) * 2017-04-04 2020-02-12 H. Hoffnabb-La Roche Ag Novel bispecific antigen binding molecules capable of specific binding to cd40 and to fap
GB201709203D0 (en) * 2017-06-09 2017-07-26 Autolus Ltd Antigen-binding domain
JP2020530993A (ja) * 2017-08-02 2020-11-05 オートラス リミテッド キメラ抗原受容体または改変ｔｃｒを発現し、選択的に発現されるヌクレオチド配列を含む細胞
US20200231679A1 (en) * 2017-08-23 2020-07-23 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and a tumor-associated antigen
JP7372920B2 (ja) * 2017-12-29 2023-11-01 セレクティス Ｃａｒ ｔ細胞の作製を改良するための方法
WO2019129850A1 (en) * 2017-12-29 2019-07-04 Cellectis Off-the-shelf engineered cells for therapy
GB201800298D0 (en) * 2018-01-09 2018-02-21 Autolus Ltd Method
US20200339687A1 (en) * 2018-01-19 2020-10-29 The Trustees Of The University Of Pennsylvania Compositions and methods for targeting gamma delta t cells with chimeric antigen receptors
PE20220278A1 (es) 2018-02-08 2022-02-25 Dragonfly Therapeutics Inc Dominios variables de anticuerpos que se dirigen al receptor nkg2d
WO2020010229A1 (en) * 2018-07-06 2020-01-09 Arizona Board Of Regents On Behalf Of The University Of Arizona Car t cell therapy to target t cell specific cancers
US20210277120A1 (en) * 2018-07-18 2021-09-09 The General Hospital Corporation Compositions and methods for treatment of t cell malignancies
GB201812650D0 (en) 2018-08-03 2018-09-19 Autolus Ltd Molecular assessment of TRBC usage
GB201817172D0 (en) 2018-10-22 2018-12-05 Autolus Ltd Antibody
GB201817822D0 (en) * 2018-10-31 2018-12-19 Autolus Ltd Binding domain
EP3919515A4 (en) * 2019-01-29 2022-11-23 Shanghai Jiao Tong University CHIMERA ANTIGEN RECEPTOR AND THEIR USE
AU2020226893A1 (en) * 2019-02-21 2021-09-23 Marengo Therapeutics, Inc. Multifunctional molecules that bind to T cell related cancer cells and uses thereof
CN110317266A (zh) * 2019-07-17 2019-10-11 东北农业大学 三种scFv抗体、其编码基因及其在制备治疗或预防O型口蹄疫病制剂中的应用
EP4121518A1 (en) * 2020-03-16 2023-01-25 Marengo Therapeutics, Inc. Engineered cell compositions and methods of use thereof
GB202004263D0 (en) 2020-03-24 2020-05-06 Autolus Ltd Antibody conjugate
GB202005216D0 (en) 2020-04-08 2020-05-20 Autolus Ltd Cell
GB202101491D0 (en) 2021-02-03 2021-03-17 Autolus Ltd Molecule
US20230133554A1 (en) 2020-04-09 2023-05-04 Autolus Limited Molecule
KR20230028242A (ko) * 2020-04-24 2023-02-28 마렝고 테라퓨틱스, 인크. T 세포 관련 암 세포에 결합하는 다중기능성 분자 및 그것의 용도
CN111537735A (zh) * 2020-05-15 2020-08-14 江西赛基生物技术有限公司 抗体检测试剂盒以及在免疫分析方面的应用
CN111549044B (zh) * 2020-07-13 2020-10-23 北京市肿瘤防治研究所 靶向trbc1 car-t细胞的制备方法与应用
US20230287345A1 (en) * 2020-08-18 2023-09-14 Medigene Immunotherapies Gmbh ENRICHMENT OF T CELLS USING AN ANTI-Cß ANTIBODY
CN116761818A (zh) * 2020-08-26 2023-09-15 马伦戈治疗公司 检测trbc1或trbc2的方法
CA3211203A1 (en) * 2021-02-17 2022-08-25 The Johns Hopkins University Methods and materials for treating clonal t cell expansions
US20220267415A1 (en) * 2021-02-17 2022-08-25 The Board Of Regents Of The University Of Texas System Multimeric sars-cov-2 binding molecules and uses thereof
GB202112923D0 (en) * 2021-09-10 2021-10-27 Ucl Business Ltd Binding domain

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU652959B2 (en) * 1990-08-09 1994-09-15 National Jewish Center For Immunology And Respiratory Medicine Producing monoclonal antibodies against human T-cell receptor elements using recombinant DNA vectors
US6790604B1 (en) * 1998-05-12 2004-09-14 Stefan A. Cohen Methods for identifying or diagnosing carcinoma cells with metastatic potential based on the measurement of lymphoid genes or their products in carcinoma cells
EP1497332A1 (en) * 2002-04-29 2005-01-19 GenPat77 Pharmacogenetics AG Bispecific antibody binding tcr and tirc7 and its use in therapy and diagnosis
RU2355703C2 (ru) * 2002-10-09 2009-05-20 Медиджен Лимитед Одноцепочечные рекомбинантные т-клеточные рецепторы
GB0304068D0 (en) * 2003-02-22 2003-03-26 Avidex Ltd Substances
US7741045B2 (en) * 2006-11-16 2010-06-22 General Electric Company Sequential analysis of biological samples
WO2009151628A2 (en) * 2008-06-12 2009-12-17 Gov't Of The Usa, As Represented By The Secretary, Department Of Health Human Services Monitoring tcr-b to determine hiv therapy and disease progression
CA2735193A1 (en) * 2008-08-26 2010-03-11 Macrogenics, Inc. T-cell receptor antibodies and methods of use thereof
WO2011090762A1 (en) * 2009-12-29 2011-07-28 Emergent Product Development Seattle, Llc Heterodimer binding proteins and uses thereof
JP6000507B2 (ja) * 2010-09-30 2016-09-28 パナソニックヘルスケアホールディングス株式会社 診療情報登録装置
JP5947311B2 (ja) * 2010-12-09 2016-07-06 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 癌を治療するためのキメラ抗原受容体改変ｔ細胞の使用
WO2013074916A1 (en) 2011-11-18 2013-05-23 Board Of Regents, The University Of Texas System Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla
PL2855667T3 (pl) * 2012-05-25 2024-03-25 Cellectis Sposoby uzyskiwania metodami inżynierii allogenicznych i opornych na immunosupresję limfocytów t do immunoterapii
US10443100B2 (en) * 2014-05-22 2019-10-15 The Scripps Research Institute Gene expression profiles associated with sub-clinical kidney transplant rejection
US20160081314A1 (en) * 2014-09-19 2016-03-24 Regeneron Pharmaceuticals, Inc. Chimeric Antigen Receptors
BR112017020750A2 (pt) * 2015-03-27 2018-06-26 Harvard College células t modificadas e métodos de produção e utilização das mesmas

Also Published As

Publication number Publication date
PL3125934T3 (pl) 2020-04-30
IL278879A (en) 2021-01-31
SG10201906460PA (en) 2019-09-27
CN106068276A (zh) 2016-11-02
MY173567A (en) 2020-02-04
JP7149304B2 (ja) 2022-10-06
PT3125934T (pt) 2019-12-16
NZ761844A (en) 2021-06-25
EP3125934A1 (en) 2017-02-08
PE20170125A1 (es) 2017-03-16
WO2015132598A1 (en) 2015-09-11
JP2017510257A (ja) 2017-04-13
KR20200027576A (ko) 2020-03-12
RU2016138421A (ru) 2018-04-05
CN106068276B (zh) 2020-09-18
BR112016020304B1 (pt) 2024-02-27
AU2019204925B2 (en) 2021-02-18
HUE047641T2 (hu) 2020-05-28
BR112016020304A2 (pt) 2017-10-17
MX2019013846A (es) 2020-02-24
SG10201906461SA (en) 2019-09-27
KR102235202B1 (ko) 2021-04-05
JP2021184773A (ja) 2021-12-09
RU2021101502A (ru) 2021-06-25
CL2016002195A1 (es) 2017-05-19
CL2019001567A1 (es) 2019-08-16
PH12020550203A1 (en) 2021-08-16
AU2019204921A1 (en) 2019-08-01
CU24475B1 (es) 2020-03-04
CN112094347A (zh) 2020-12-18
AU2015225944A1 (en) 2016-09-01
PH12016501646A1 (en) 2017-02-06
NZ761848A (en) 2021-06-25
CA2940564A1 (en) 2015-09-11
JP6767931B2 (ja) 2020-10-14
RU2016138421A3 (es) 2018-07-25
RU2018140694A (ru) 2018-12-10
DK3125934T3 (da) 2020-02-03
CA2940564C (en) 2021-06-29
EP3241561A1 (en) 2017-11-08
NZ723307A (en) 2021-06-25
US20170334998A1 (en) 2017-11-23
AU2019204925A1 (en) 2019-08-01
CN112094353A (zh) 2020-12-18
SG11201606583VA (en) 2016-09-29
AU2019204921C1 (en) 2021-05-13
AU2019204921B2 (en) 2021-02-18
KR102088082B1 (ko) 2020-03-11
CL2019001568A1 (es) 2019-08-16
RU2744046C2 (ru) 2021-03-02
KR20200027577A (ko) 2020-03-12
PE20211887A1 (es) 2021-09-22
IL278878A (en) 2021-01-31
ES2758173T3 (es) 2020-05-04
AU2015225944B2 (en) 2019-07-11
JP6767872B2 (ja) 2020-10-14
IL247110A0 (en) 2016-09-29
EP3125934B1 (en) 2019-10-23
JP2020099356A (ja) 2020-07-02
US20170066827A1 (en) 2017-03-09
MX2019013845A (es) 2020-02-24
KR102235201B1 (ko) 2021-04-05
KR20160127130A (ko) 2016-11-02
MX2016010856A (es) 2017-04-13
JP2017143838A (ja) 2017-08-24
IL278878B (en) 2022-07-01

Similar Documents

Publication Publication Date Title
CL2018003096A1 (es) Receptor antigenico quimerico (car) con dominios de union a antigenos a la region constante del receptor de celulas t beta (divisional de la solicitud 2195-2016).
CL2018003216A1 (es) Célula (divisional de solicitud cl 1314-2017).
CL2018000270A1 (es) Constructos de anticuerpo para cd70 y cd3.
CL2018000269A1 (es) Constructos de anticuerpo para flt3 y cd3
MX2022014867A (es) Anticuerpos especificos del receptor de poliovirus humano (rvp).
CR20180461A (es) Receptores de antígenos quiméricos y células t y métodos de uso
CL2018000263A1 (es) Constructos de anticuerpo biespecificos que se unen a egfrviii y cd3.
CL2018003406A1 (es) Agonista del receptor de glucocorticoides e inmunoconjugados del mismo.
CR20190050A (es) Receptores de antígenos quiméricos dirigidos a bcma y métodos de uso de estos
CR20210084A (es) Receptores quiméricos y métodos de uso de los mismos (divisional 2018-0480)
AR117685A1 (es) Antígeno quimérico y receptores de células t y métodos de uso
CR20170436A (es) Receptores de antígeno químericos anti-dll3 y métodos de uso
MX2019015352A (es) Linfocitos t con receptor de antigeno quimerico (car) para receptor 1 huerfano tipo receptor de tirosina cinasa (ror 1).
UY35468A (es) Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
DOP2013000260A (es) Uso del anticuerpo anti-cd19 inmunoconjugado con maitansinoide para el tratamiento del síntoma tumores de células b
MX2016011748A (es) Anticuerpos humanizados con estabilidad incrementada.
AR102495A1 (es) Anticuerpos contra el dominio 3 de la inmunoglobulina y de la mucina del linfocito t (tim3) y métodos de uso
AR105561A1 (es) Constructos de anticuerpo para el receptor de la tirosina quinasa (flt3) y el antígeno cd3
AR101592A1 (es) Tratamiento de cáncer usando un receptor quimérico de antígeno cd123